Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (311-320 of 442) with videos related to

Pageof 45
Sort By:
Journal for Immunotherapy of Cancer|April 22, 2017
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesMatthew J Reilley, Ann Bailey, Vivek Subbiah, et al.
NPJ Precision Oncology|January 13, 2026
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD AndersonJeong Uk Lim, Heather Y Lin, Lei Kang, et al.
Scientific Reports|November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitorsVikas Dembla, Roman Groisberg, Ken Hess, et al.
Investigational New Drugs|April 4, 2018
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumorsCarol Aghajanian, Katherine M Bell-McGuinn, Howard A Burris, et al.
The Oncologist|May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland CancersXiuning Le, Christina Baik, Jessica Bauman, et al.
Cancer|October 29, 2020
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancersFilip Janku, Divya Sakamuri, Shumei Kato, et al.
Cancer Treatment Reviews|June 24, 2014
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitorsChristian Rolfo, Elisa Giovannetti, David S Hong, et al.
Cancer Research Communications|December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid MalignanciesVivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.
JCO Precision Oncology|October 31, 2017
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine StudyApostolia-Maria Tsimberidou, David S Hong, Yang Ye, et al.
The Oncologist|March 30, 2021
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical TrialsRyan W Huey, Goldy C George, Penny Phillips, et al.
Pageof 45

Showing results (311-320 of 442) with videos related to

Sort By:
Pageof 45
Journal for Immunotherapy of Cancer|April 22, 2017
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesMatthew J Reilley, Ann Bailey, Vivek Subbiah, et al.
NPJ Precision Oncology|January 13, 2026
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD AndersonJeong Uk Lim, Heather Y Lin, Lei Kang, et al.
Scientific Reports|November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitorsVikas Dembla, Roman Groisberg, Ken Hess, et al.
Investigational New Drugs|April 4, 2018
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumorsCarol Aghajanian, Katherine M Bell-McGuinn, Howard A Burris, et al.
The Oncologist|May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland CancersXiuning Le, Christina Baik, Jessica Bauman, et al.
Cancer|October 29, 2020
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancersFilip Janku, Divya Sakamuri, Shumei Kato, et al.
Cancer Treatment Reviews|June 24, 2014
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitorsChristian Rolfo, Elisa Giovannetti, David S Hong, et al.
Cancer Research Communications|December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid MalignanciesVivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.
JCO Precision Oncology|October 31, 2017
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine StudyApostolia-Maria Tsimberidou, David S Hong, Yang Ye, et al.
The Oncologist|March 30, 2021
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical TrialsRyan W Huey, Goldy C George, Penny Phillips, et al.
Pageof 45